Evidence map›Paper›PMID 41808771›Full record

ReviewFrontiers in cellular and infection microbiology2025

Nanotech meets antibiotics: nucleotide antibiotics delivered by lipid nanoparticles.

Bookun Kim, Dajeong Kim, Choong-Min Ryu

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bookun KimMolecular Phytobacteriology Laboratory, Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Dajeong KimMolecular Phytobacteriology Laboratory, Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Choong-Min RyuMolecular Phytobacteriology Laboratory, Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global spread of multidrug-resistant bacteria poses a serious challenge to effective therapy and public health. The rising resistance to small-molecule antibiotics underscores the limitations of conventional antimicrobial strategies and highlights the urgent need for alternative therapeutic modalities. Lipid nanoparticles (LNPs) have emerged as efficient vehicles for delivering genetic materials, as exemplified by their success in mRNA vaccines. Recent studies suggest that LNPs can also be harnessed to suppress bacterial proliferation and counteract antibiotic resistance through the targeted delivery of nucleic acid cargo. In this review, we discuss recent advances in nanotechnology-based platforms for nucleic acid delivery into prokaryotic systems, with a particular focus on LNPs. We highlight LNPs as a promising delivery system for modulating antimicrobial resistance and bacterial fitness genes. Additionally, we outline key components and formulation strategies required to enable effective nucleic acid delivery against multidrug-resistant bacteria.

Indexed as

Anti-Bacterial AgentsDrug CarriersDrug Delivery SystemsLipidsNanoparticlesNanotechnologyNucleotidesBacteriaDrug Resistance, Multiple, BacterialHumansLiposomesAnti-Bacterial AgentsDrug CarriersLipid NanoparticlesLipidsLiposomesNucleotidesantimicrobial resistant bacteriabacteria-targeting lipid nanoparticleslipid nanoparticles (LNPs)microfluidicsnucleotide antibioticsnucleotide delivery

Identifiers

PMID41808771
PMCPMC12968294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.